#United States #San Francisco #Hagens Berman #GeneDx Holdings #WGS

Ongoing Investigation Surrounding GeneDx Holdings (WGS)

Hagens Berman Sobol Shapiro LLP, a recognized leader in securities litigation, is currently conducting an investigation into GeneDx Holdings, Inc. (NASDAQ: WGS) and its top executives. This action follows a dramatic downturn in the company’s stock price, which plummeted by 49% following the release of its first-quarter financial results for 2026. The driving forces behind this investigation involve serious allegations that the company misrepresented the benefits associated with its acquisition of Fabric Genomics.

Background of the Lawsuit

On May 5, 2026, GeneDx reported disheartening financial results that indicated a tenfold increase in net loss when compared to the previous year. The financial report was particularly alarming due to an impairment charge totaling $31.2 million. This charge represents approximately 94% of the cash GeneDx paid for Fabric Genomics just one year ago. Such dramatic figures have raised eyebrows amongst investors and analysts alike, prompting legal scrutiny.

The manipulation alleged in the class action lawsuit stems from the company’s past representations that the acquisition of Fabric Genomics would significantly enhance operational efficiency and lead to a profitable future. However, the firm’s Q1 report negated these claims, revealing that the underlying business model may not achieve the anticipated synergies. Alarmingly, Fabric Genomics also reported a revenue miss of $2.5 million, which was identified as a critical factor contributing to GeneDx’s staggering losses, further intensifying concerns among stakeholders.

Changes in Leadership

In response to the financial fallout, GeneDx recently appointed Mark Gardner as the new President. He replaces former leadership amidst speculation that their previous decisions may have contributed to the current crisis. Hagens Berman is now investigating the possibility that this leadership shift is directly linked to the failures and misleading projections that led to the company’s substantial market devaluation.

Reed Kathrein, the partner at Hagens Berman overseeing this case, expressed serious concerns about the misalignment between GeneDx's public commitments to its investors and the actual performance of its acquisitions. “Investors were given an optimistic narrative about technological synergies, only to face a shocking impairment charge,” Kathrein stated. "Our investigation aims to determine if GeneDx’s executives were aware of the discrepancies between public projections and the company’s internal challenges."

Implications for Investors

Investors in GeneDx Holdings who have experienced significant financial losses during the class period of April 16, 2025, to May 4, 2026, are encouraged to reach out to Hagens Berman for assistance. The firm is particularly focused on collecting evidence and testimonies that may provide additional insights into GeneDx's financial and operational conduct.

Potential claimants can visit the firm's dedicated webpage or contact them directly to discuss their experiences and see how they might contribute to the ongoing investigation. Those with non-public information regarding the company are also encouraged to explore whistleblower options, which may offer avenues for recovery and protection.

About Hagens Berman

As a global plaintiffs' rights firm, Hagens Berman has established a strong reputation for its focus on corporate accountability. The firm represents various stakeholders including investors and whistleblowers, and has achieved substantial recoveries for clients harmed by corporate misconduct. With a track record that includes securing over $2.9 billion in litigation outcomes, Hagens Berman remains at the forefront of financial justice. For the latest updates, check out their social media at @ClassActionLaw.

In light of recent events in the market, investors are reminded to stay informed and exercise diligence before making investment decisions. This ongoing investigation into GeneDx Holdings is just one of many that highlight the importance of transparency and accuracy in corporate reporting.